Combined Let-7a and H19 Signature: A Prognostic Index of Progression-Free Survival in Primary Breast Cancer Patients

Qiannan Guo; Runyao Wen; Bin Shao; Yudong Li; Xin Jin; Heran Deng; Jiannan Wu; Fengxi Su; Fengyan Yu

추천

검색

자료유형: 학술저널

저자정보: Qiannan Guo (Sun Yat-sen University) Runyao Wen (Sun Yat-sen University) Bin Shao (Peking University Cancer Hospital and Institute) Yudong Li (Sun Yat-sen University) Xin Jin (Sun Yat-sen University) Heran Deng (Sun Yat-sen University) Jiannan Wu (Sun Yat-sen University) Fengxi Su (Sun Yat-sen University) Fengyan Yu (Sun Yat-sen Memorial Hospital Sun Yat-Sen University China)

저널정보: 한국유방암학회 Journal of Breast Cancer Journal of Breast Cancer Vol.21 No.2

발행연도: 2018.1

수록면: 142 - 149 (8page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: The long non-coding RNA H19, a conservatively imprinted gene, acts as a molecular sponge for the let-7 family, which has been identified as a set of tumor suppressors. However, the combined prognostic value of H19 and let-7a signature in breast cancer patients remains unclear. Methods: In this research we assessed the prognostic value of the combined H19 and let-7a signature in breast cancer patients by retrospectively reviewing that data of 79 patients who underwent neoadjuvant chemotherapy; we also investigated the expression and function of H19 in breast cancer cell lines in vitro. Survival data were calculated using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate survival analyses were conducted using the Cox proportional hazards regression method. As determined using X-tile, the optimal cutoff value for the risk score to assess progression-free survival (PFS) based on the combined signature was –0.1. Results: Patients with an overall positive treatment response had higher let-7a and lower H19 levels. In addition, let-7a expression was negatively correlated with H19 expression. Patients with a risk score of >–0.1 had shorter overall survival and PFS. In vitro data showed that chemoresistant cell lines exhibit higher H19 and lower let-7a levels and knockdown H19 restores paclitaxel sensitivity. Conclusion: Our results suggest that the combined let-7a and H19 signature is a novel prognostic factor for breast cancer patients treated with neoadjuvant chemotherapy.

참고문헌 (19)

참고문헌 신청

Forouzanfar MH / 2011 / Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis / Lancet 378:1461~1484

Kaufmann M / 2007 / Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 / Ann Oncol 18:1927~1934

Thum T / 2015 / Long noncoding RNAs and microRNAs in cardiovascular pathophysiology / Circ Res 116:751~762

Voortman J / 2010 / MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma / Cancer Res 70:8288~8298

He FC / 2015 / Expression of circulating microRNA-20a and let-7a in esophageal squamous cell carcinoma / World J Gastroenterol 21:4660~4665

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!